VP Vodis Pharmaceuticals Inc

Vodis Pharmaceuticals Inc. (CSE:VP) (FSE:1JV) ("Vodis" or the "Company") announces that Mr. Sean Côté has been appointed as the Company’s new Chief Executive Officer and a director on the resignation of Mr. Otto Folprecht. 

Mr. Côté is a multitalented, experienced operations executive with a proven ability to lead the growth and development of dynamic entrepreneurial enterprises through assembling high-performing teams, maximizing revenue generating opportunities, and increasing operational efficiencies. Mr. Côté sold his privately held company in 2008 and remained with the purchasing company for over 7 years where he contributed to that company’s successes, as revenues over that same period were ten times greater than when Mr. Côté's company was acquired. He has brokered multi-million dollar contracts with national and international corporations, penetrated untapped markets, and developed industry-leading products and services. He has led negotiations to acquire several regional companies. He has also managed and led integrations arising from 2 national acquisitions, and skillfully handled all change-related challenges to ensure rapid assimilation. “During the due diligence period over the past few weeks I definitely see the opportunity that Vodis represents.  Now the focus of the management team will be to overcome some development hurdles and apply our focus to growing shareholder value,” commented Mr. Cote.

About Vodis Pharmaceuticals Inc.

Vodis is one of North America’s foremost brand names in the medical and recreational marijuana business with operations in both the United States and Canada. Its master grow teams have consistently won or placed at each competition they have entered with their “VIP” brand. The Company, with facilities in BC and Washington State, is also actively looking into expansion opportunities in other countries and states in the United States.

While Vodis and its subsidiaries cannot have any interest whatsoever in any proceeds as a result of production, processing or retail activities in the United States, it can license its brand, production and consulting services to approved Washington State license holders to ensure that all products produced under the Vodis program and/or associated under the VIP brand meet or exceed the Vodis brand quality standards.

For further information please contact:

Sean CôtéChief Executive OfficerVodis Innovative Pharmaceuticals Inc 8788 River Rd, Delta, V4G 1B4, CanadaCell: 604-312-8110 Fax: +1 (877) 398-5278Website: www.vodis.ca 

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

Forward-Looking Information:

Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “expects” or “it is expected”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including: the use of proceeds of this financing. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statements or forward-looking information that is incorporated by reference herein, except as required by applicable securities laws.